6926-09-6 Usage
Description
Boc-Glycine hydrazide, also known as N-carbobenzoxyglycine hydrazide, is an organic compound that serves as a crucial building block in the synthesis of various pharmaceuticals and organic compounds. It is characterized by its reactivity and versatility in chemical reactions, making it a valuable component in the development of new drugs and chemicals.
Uses
Used in Pharmaceutical Industry:
Boc-Glycine hydrazide is used as a pharmaceutical intermediate for the synthesis of various drugs and medications. Its application in this industry is due to its ability to react with other compounds to form new molecules with potential therapeutic properties.
Used in Organic Synthesis:
In the field of organic synthesis, Boc-Glycine hydrazide is utilized as an intermediate for the production of a wide range of organic compounds. Its use in this industry is attributed to its reactivity and capacity to form diverse chemical structures, which can be further modified for specific applications.
Used in Laboratory Research and Development:
Boc-Glycine hydrazide is also employed in laboratory research and development processes, where it is used to explore new chemical reactions and synthesize novel compounds. Its application in this context is due to its potential to contribute to the discovery of new drugs and materials with various properties and functions.
Used in Chemical Production Process:
Lastly, Boc-Glycine hydrazide is used in the chemical production process, where it plays a role in the manufacturing of various chemicals and materials. Its use in this industry is a result of its ability to improve the efficiency and effectiveness of chemical synthesis, leading to the production of high-quality products.
Synthesis
N-Protected Hydrazides 2a-l; General Procedure The protected amino acid 1 (2 equiv) and EDAC (2 equiv) were dissolved in the minimum amount of CH2Cl2 at 0 °C. The mixture was stirred at 0 °C for 2 h. PhthNNH2 (1 equiv) was added and the mixture was stirred at 0 °C for 1 h and then at r.t. overnight. Distillation of the solvent under reduced pressure gave a product which was dissolved in EtOAc and washed successively with 1 M KHSO4, sat. aq NaHCO3, and brine. The organic layer was then dried (Na2SO4), filtered, and concentrated in vacuo. The residue was precipitated with Et2O to yield compound 2. If necessary, the residue was purified by column chromatography (silica gel, hexane- EtOAc, 3:7 to 7:3). Compounds 4a-l; General Procedure Aminomethylated polystyrene resin (3 equiv; 1.1 mmol/g, 100-200 mesh) was conditioned for 10 min at r.t. in CH2Cl2. Then 2 (1 equiv) was added, and the mixture was slowly stirred for 24 h at r.t. The mixture was filtered and the solvent was evaporated in vacuo to give product 4. Compound 4h, yield 89%.
Check Digit Verification of cas no
The CAS Registry Mumber 6926-09-6 includes 7 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 4 digits, 6,9,2 and 6 respectively; the second part has 2 digits, 0 and 9 respectively.
Calculate Digit Verification of CAS Registry Number 6926-09:
(6*6)+(5*9)+(4*2)+(3*6)+(2*0)+(1*9)=116
116 % 10 = 6
So 6926-09-6 is a valid CAS Registry Number.
InChI:InChI=1/C7H15N3O3/c1-7(2,3)13-6(12)9-4-5(11)10-8/h4,8H2,1-3H3,(H,9,12)(H,10,11)
6926-09-6Relevant articles and documents
Targeting RECQL5 Functions, by a Small Molecule, Selectively Kills Breast Cancer in Vitro and in Vivo
Chakraborty, Saikat,Dutta, Kartik,Gupta, Pooja,Das, Anubrata,Das, Amit,Ghosh, Sunil Kumar,Patro, Birija Sankar
, p. 1524 - 1544 (2021/02/16)
Clinical and preclinical data reveal that RECQL5 protein overexpression in breast cancer was strongly correlated with poor prognosis, survival, and therapeutic resistance. In the current investigation, we report design, synthesis, and specificity of a small molecule, 4a, which can preferentially kill RECQL5-expressing breast cancers but not RECQL5 knockout. Our stringent analysis showed that compound 4a specifically sensitizes RECQL5-expressing cancers, while it did not have any effect on other members of DNA RECQL-helicases. Integrated approaches of organic synthesis, biochemical, in silico molecular simulation, knockouts, functional mutation, and rescue experiments showed that 4a potently inhibits RECQL5-helicase activity and stabilizes RECQL5-RAD51 physical interaction, leading to impaired HRR and preferential killing of RECQL5-expressing breast cancer. Moreover, 4a treatment led to the efficient sensitization of cisplatin-resistant breast cancers but not normal mammary epithelial cells. Pharmacologically, compound 4a was orally effective in reducing the growth of RECQL5-expressing breast tumors (human xenograft) in NUDE-mice with no appreciable toxicity to the vital organs.
COMBINATION TREATMENTS COMPRISING ADMINISTRATION OF 1H-PYRAZOLO[4,3-B]PYRIDINES
-
Page/Page column 111; 122, (2019/07/19)
The present invention provides 1H-pyrazolo[4,3-b]pyridin-7-amines of formula (I) as PDE1 inhibitors together with a second compound useful in the treatment of a neurodegenerative disorder and their combined use as a medicament, in particular for the treatment of neurodegenerative and/or cognitive disorders.
COMBINATION TREATMENTS COMPRISING ADMINISTRATION OF 1H-PYRAZOLO[4,3-B]PYRIDINES
-
Page/Page column 108-109, (2019/07/19)
The present invention provides 1H-pyrazolo[4,3-b]pyridin-7-amines of formula (I) as PDE1 inhibitors together with a second compound which compound is useful in the treatment of a psychiatric disorder and their combined use as a medicament, in particular for the treatment of psychiatric and/or cognitive disorders.
